Julie Jaffray
University of California-San Diego, CA·Medicine & Clinical Research·Early-career
Hospital-acquired venous thromboembolism (VTE) is a blood clot that forms in the deep veins or the lungs during a hospital stay. Its rate in hospitalized children has risen by 70–200%, leading to more illness, more deaths and longer stays.
- Fields
Medicine & Clinical Research
Public Health & Epidemiology
- Topics
venous thromboembolism
hospital-acquired thrombosis
deep vein thrombosis
- Grants
- 2 known grants, through Jul 2028
What they work on
- Prospectively validate a pediatric hospital-acquired venous thromboembolism (VTE) risk assessment model from the CHAT Consortium, using a case-control design and electronic medical record review.
- Measure how often hospitalized children bleed on and off anticoagulants (blood thinners) and characterize these events through medical record review.
- Identify barriers to inpatient teams using VTE risk models, through focus groups and semi-structured interviews analyzed with qualitative thematic methods.
- Update and internally validate a VTE risk model for children in the intensive care unit using the CHAT 1901 dataset of more than 4,600 patients, with multivariable Cox regression and imputation of missing data.
- Identify predictors of hospital-associated bleeding in critically ill children from the CHAT 1901 dataset, using univariate and then multivariable Cox proportional hazards models.
More about the research
Blood thinners could prevent many of these clots, but they raise the risk of bleeding. Because no one knows which children are at highest risk, the standard of care is usually not to give preventive medication at all. This research aims to identify children at high clot risk but low bleeding risk, so that future prevention trials can enroll the right patients. The work draws on the Children's Hospital Acquired Thrombosis (CHAT) Consortium, a multi-center network of children's hospitals.
Why it matters
VTE is the second leading cause of preventable harm in hospitalized children. Validated tools that predict both clot and bleeding risk could let clinicians target preventive blood thinners to the children most likely to benefit while avoiding harm to others. These tools could also set the stage for prevention trials that may reduce clot-related illness, long-term leg pain and venous insufficiency, and death.
Known grants
From NIH and NSF research grants. Labs often have other funding we can't see.
Secondary Analysis of the Children's Healthcare Advancements in Thrombosis (CHAT) Consortium Dataset
NIH · Aug 2026 – Jul 2028
Validation of a pediatric thrombosis risk assessment model and characterization of bleeding in hospitalized children through the Children's Hospital Acquired Thrombosis (CHAT) Consortium
NIH · Aug 2022 – Jul 2027
Closest labs
Anthony Sochet
Johns Hopkins University, MD·Medicine & Clinical Research·Early-career
Determine how the intensity of invasive mechanical ventilation affects functional fibrinolysis, the body's ability to break down clots, in critically ill children.
Denise Hasson
New York University, NY·Medicine & Clinical Research·Early-career
Characterize baseline nutritional status in 200 high-risk pediatric ICU patients using dietary questionnaires, malnutrition screening, arm circumference, skinfold thickness, grip strength and muscle ultrasound, and test whether these risk subtypes predict acute kidney injury.
Charles Lowenstein
Johns Hopkins University, MD·Medicine & Clinical Research
Test whether BCOR, a gene-silencing protein, suppresses Factor VII production in liver cells by controlling the epigenetic complexes PRC1.1 and ATAC, which regulate how DNA is packaged and read.
The school
University of California-San Diego: 84 labs on PI Pages, $1.9B a year on research, 637 research doctorates a year.
Reach out
A start for your email. Fill in the brackets.